1. Signaling Pathways
  2. Neuronal Signaling
  3. α-synuclein

α-synuclein

α-Syn

α-Synuclein is an abundant neuronal protein that is highly enriched in presynaptic nerve terminals. α-synuclein regulates synaptic vesicle trafficking and subsequent neurotransmitter release. Genetics and neuropathology studies link α-synuclein to Parkinson's disease (PD) and other neurodegenerative disorders. Accumulation of misfolded oligomers and larger aggregates of α-synuclein defines multiple neurodegenerative diseases called synucleinopathies, but the mechanisms by which α-synuclein acts in neurodegeneration are unknown.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-159941
    tau-0N4R-IN-1
    Inhibitor
    tau-0N4R-IN-1 (Compound 6T) is an BBB-penetrable inhibitor of tau 0N4R oligomerization. tau-0N4R-IN-1 effectively inhibits the fibrosis of tau 0N4R, 2N3R, and 2N4R, exhibits an anti-seeding effect on tau in vitro, reduces the oligomerization of α-syn dose-dependently, and prevents formation of α-syn inclusions. tau-0N4R-IN-1 is stable in mouse microsomes and reduces plaques in brain tissues from AD patients. tau-0N4R-IN-1 has good pharmacokinetic properties in mice.
    tau-0N4R-IN-1
  • HY-P5046
    α-Synuclein (71-82) (human)
    α-Synuclein (71-82) (human) is the 71-82 fragment of α-Synuclein. α-Synuclein is an abundant neuronal protein that is highly abundant in presynaptic nerve terminals. α-Synuclein is a biomarker for Parkinson's disease (PD).
    α-Synuclein (71-82) (human)
  • HY-170381
    α-syn aggregation inhibitor-1
    Inhibitor
    α-syn aggregation inhibitor-1 (Compound 2e) is an inhibitor for α-syn aggregation. α-syn aggregation inhibitor-1 inhibits the cell viability of SH-SY5Y.
    α-syn aggregation inhibitor-1
  • HY-157225
    Brazilin-7-acetate
    Inhibitor
    Brazilin-7-acetate (B-7-A) is an inhibitor of α-synuclein (α-Syn) aggregates. Brazilin-7-acetate inhibits the formation of α-synuclein fibril, mitigates cytotoxicity, and decreases oxidative stress. Brazilin-7-acetate can be used in the research of Parkinson's disease.
    Brazilin-7-acetate
  • HY-147666
    α-Synuclein inhibitor 4
    Inhibitor
    α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 0.98 μM and inhibition ratio at 30 μM of 91.2%.
    α-Synuclein inhibitor 4
  • HY-N0901AR
    Corynoxine B (Standard)
    Inhibitor
    Corynoxine B Standard is an analytical standard for Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is an alkaloid-type autophagy inducer and α-synuclein aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances the clearance of α-synuclein (α-syn) in Parkinson's disease mice.
    Corynoxine B (Standard)
  • HY-P10360
    Tat-βsyn-degron
    Degrader
    Tat-βsyn-degron is an α-synuclein knockdown peptide that effectively degrades α-synuclein protein via the proteasome pathway. Tat-βsyn-degron effectively reduces α-synuclein protein levels in primary rat cortical neuron cultures. In a Parkinson's mouse toxicity model, Tat-βsyn-degron can alleviate parkinsonian toxin-induced neuronal damage and movement disorders.
    Tat-βsyn-degron
  • HY-161328
    MAO-B-IN-31
    Inhibitor
    MAO-B-IN-31 (Compound 30) is an effective and selective inhibitor of monoamine oxidase B (monoamine oxidase B). The IC50 value is 41 nM. MAO-B-IN-31 also inhibits α-syn and tau aggregation. MAO-B-IN-31 has neuroprotective activity.
    MAO-B-IN-31
  • HY-D0914A
    Fast green FCF free acid
    Inhibitor
    Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as , P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function.
    Fast green FCF free acid
  • HY-175308
    α-synuclein-IN-15
    Inhibitor
    α-synuclein-IN-15 (Compound 1) is an inhibitor targeting the fibrillation growth of α-synuclein (IC50=18 μM). α-synuclein-IN-15 is promising for research of neurodegenerative diseases, such as Parkinson's disease (PD) and Lewy body dementia (LBD).
    α-synuclein-IN-15
  • HY-157806
    α-Synuclein inhibitor 12
    Inhibitor
    α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases.
    α-Synuclein inhibitor 12
  • HY-P10404
    PDpep1.3
    Antagonist
    PDpep1.3 is a peptide inhibitor of α-synuclein that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions.
    PDpep1.3
  • HY-147669
    α-Synuclein inhibitor 7
    Inhibitor
    α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.95 μM and inhibition ratio at 30 μM of 85.8%.
    α-Synuclein inhibitor 7
  • HY-147644
    α-Synuclein inhibitor 3
    Inhibitor
    α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research.
    α-Synuclein inhibitor 3
  • HY-N0413R
    Hupehenine (Standard)
    Inhibitor
    Hupehenine (Standard) is the analytical standard of Hupehenine (HY-N0413). This product is intended for research and analytical applications. Hupehenine is an orally active isosteroidal alkaloid that can be extracted from F. hupehensis. Hupehenine exhibits activities such as antitussive, expectorant, anticancer, and antiparasitic. In vitro, Hupehenine can also inhibit α-synuclein seeded fibril formation, making it applicable for the research of Parkinson's disease and other related disorders.
    Hupehenine (Standard)
  • HY-163519
    α-Synuclein inhibitor 13
    Inhibitor
    α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research.
    α-Synuclein inhibitor 13
  • HY-147667
    α-Synuclein inhibitor 5
    Inhibitor
    α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.22 μM and inhibition ratio at 30 μM of 94.3%.
    α-Synuclein inhibitor 5
  • HY-159152
    PQM-164
    Inhibitor
    PQM-164 (Compound 3e) has antioxidant activity (IC50: 0.93 μM for DPPH radical). PQM-164 shows anti-inflammatory activity against 6-OHDA (HY-B1081A)-induced neuronal damage in activated microglial cells. PQM-164 decreases the accumulation of α-synuclein. PQM-164 promotes nuclear translocation of Nrf2 and its transcriptional activity. PQM-164 can be used for research of Parkinson’s disease.
    PQM-164
  • HY-149065
    D-685
    Inhibitor
    D-685, a prodrug of D-520, exhibits higher in vivo anti-Parkinsonian efficacy in a reserpinized Parkinson's disease (PD) animal model than the parent D-520. D-685 reduces accumulation of human α-synuclein (α-syn) protein. D-685 exhibits facile brain penetration.
    D-685
  • HY-121252A
    Dopal (purity>80%)
    Inhibitor
    Dopal (purity>80%) is an aldehyde that can be generated in Parkinson's disease by enzymatic degradation of dopamine. Dopal (purity>80%) can generate reactive oxygen species (ROS), and triggers aggregation of α-synuclein. Dopal (purity>80%) elicits α-synuclein accumulation and hampers α-synuclein clearance in primary neurons.
    Dopal (purity>80%)

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.